This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reams, G. P. Articles by Gaddy, P. Search for Related Content PubMed PubMed Citation Articles by Reams, G. P. Articles by Gaddy, P.

Hypertension, Vol 8, 290-297, Copyright © 1986 by American Heart Association

ARTICLES

Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin- angiotensin-aldosterone system

GP Reams, JH Bauer and P Gaddy

Thirteen patients were entered into a protocol to assess the safety and efficacy of enalapril (MK 421), 5 to 20 mg b.i.d., and hydrochlorothiazide, 50 to 100 mg daily, for the treatment of renovascular hypertension. Specifically monitored were the effects of therapy on blood pressure and pulse, renal function, and the renin- angiotensin-aldosterone axis. Enalapril and hydrochlorothiazide therapy produced excellent control of blood pressure with no adverse side effects. After approximately 8 weeks of therapy, renal vascular resistance was decreased and no adverse effects on glomerular filtration rate or renal blood flow were noted, except in one patient with a functional unilateral stenotic kidney. Patients receiving enalapril and hydrochlorothiazide showed stimulation of plasma renin activity and suppression of plasma angiotensin II, although the initial degree of suppression was not sustained in all patients during prolonged therapy. Although plasma aldosterone concentration was initially suppressed, the degree of suppression was not sustained. Nine patients have been followed for an additional 6 months; none have experienced further progression of renal disease, as assessed by repeated measurements of glomerular filtration and effective renal plasma flow. These results suggest that combined enalapril and hydrochlorothiazide therapy is safe and effective in the medical management of renovascular hypertension and that blood pressure control may be achieved in the absence of sustained interruption of the renin- angiotensin-aldosterone system.

This article has been cited by other articles:

				S. J. Mann and T. G. Pickering Detection of Renovascular Hypertension: State of the Art: 1992 Ann Intern Med, November 15, 1992; 117(10): 845 - 853. [Abstract] [PDF]

				H. Kumagai, H. Suzuki, S. Matsukawa, M. Ryuzaki, and T. Saruta Captopril Therapy Following Percutaneous Transluminal Angioplasty for Bilateral Renal Artery Stenosis Arch Intern Med, September 1, 1989; 149(9): 1973 - 1976. [Abstract] [PDF]

				G. P. Reams and J. H. Bauer Effect of Enalapril in Subjects With Hypertension Associated With Moderate to Severe Renal Dysfunction Arch Intern Med, November 1, 1986; 146(11): 2145 - 2148. [Abstract] [PDF]